 |
|
|
|
|
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Ghribi O. on NEWS: Weight, Weight, Don’t Tell Me—Leptin Lowers AD Risk?, In a paper in the Journal of Alzheimer's Disease, we demonstrate that the oxysterol... 22 Dec 2009.
|
|
|
 |
|
|
Ghribi O. on PAPER: King ME. et al., 2006, Whether accumulation of Aβ peptide, hyperphosphorylation of tau, or cell death is generated... 4 Dec 2006.
|
|
|
|
|
|
Ghribi O. on NEWS: Aβ Assault on Neurons Targets ER, Calcium, In a recent review paper (Ghribi, 2006), we have addressed the role of ER in Alzheimer disease... 1 Aug 2006.
|
|
|
|
|
|
Ghribi O. on NEWS: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet, Kang and co-workers examined the effect of PS1 and PS2 deficiency on PI3/Akt and ERK pathways,... 25 Jul 2005.
|
|
|
|
|
|
Ghribi O. on NEWS: Lost in Translation: Memories Need MAP to Find Their Way Home, ERK activation has been associated with the regulation of three major features of relevance to... 8 Feb 2004.
|
|
|
|
|
|
Ghribi O. on NEWS: GSK3β—Not Just for Tauists Anymore, The findings by Emamian and colleagues provide advances in our understanding of the mechanisms... 31 Jan 2004.
|
|
|
|
|
|
Ghribi O. on NEWS: Does ER Stress Protein Contribute to Biopolar Disorder?, ER disturbance may result from protein misfolding or from perturbation in the ER calcium... 16 Sep 2003.
|
|
|
|
|
|
Ghribi O. on NEWS: Lithium Hinders Aβ Generation, Buffing Up GSK as Drug Target, We were the first to show that lithium fully prevents the activation of GSK-3 alpha in vivo.... 13 Jun 2003.
|
|
|
|
|
|
Ghribi O. on PAPER: Shastry BS. et al., 2003, Recommendation Only. 16 Mar 2003.
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
